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OPEN
ORIGINAL ARTICLE
Insight into synergetic mechanisms of tetracycline and
the selective serotonin reuptake inhibitor, sertraline, in
a tetracycline-resistant strain of Escherichia coli
Lili Li1, Soﬁe Kromann2, John Elmerdahl Olsen2, Søren Wedel Svenningsen3 and Rikke Heidemann Olsen2
Sertraline, an antidepressive drug, has been reported to inhibit general bacterial efﬂux pumps. In the present study, we report
for the ﬁrst time a synergistic effect of sertraline and tetracycline in a TetA-encoded tetracycline-resistant strain of Escherichia
coli. Synergy between sertraline and tetracycline in an E. coli strain with TetA-mediated tetracycline resistance (E. coli
APEC_O2) was assessed by the MIC and checkerboard assays. The global transcriptome of E. coli APEC_O2 exposed to ½ MIC
concentrations of sertraline and/or tetracycline was analyzed to elucidate the interaction mechanism between sertraline and
tetracycline. The fractional inhibitory concentration index for tetracycline and sertraline in E. coli APEC_O2 was 0.5. In addition,
in the presence of ½ MIC of sertraline, the sensitivity of E. coli APEC_O2 to tetracycline could be restored according to clinical
standards (from 64 to 4 mg l−1). RNA data suggest changes in respiration that is likely to decrease intracellular pH and thereby
the proton-motive force, which provides the energy for the tetracycline efﬂux pump. Furthermore, sertraline and tetracycline may
induce a change from oxidation to fermentation in the E. coli, which further decreases pH, resulting in cell death. This study
shows that sertraline interacts with tetracycline in a synergistic and AcrAB-TolC pump-independent manner. The combinational
treatment was further shown to induce many changes in the global transcriptome, including altered tetA and tetR expression.
The results indicate that sertraline may be used as a helper compound with the aim to reverse tetracycline resistance encoded
by tetA.
The Journal of Antibiotics (2017) 70, 944–953; doi:10.1038/ja.2017.78; published online 12 July 2017
INTRODUCTION
Several neuroleptic drugs; for example, phenothiazine and selective
serotonin reuptake inhibitors, have been reported to have anti-
microbial properties in high concentration, while having anti-
microbial ‘helper-compound’ properties in lower concentration.1–4
For the latter group, evidence suggests that the effect is due to
inhibition of broad-speciﬁcity efﬂux pumps.5 These efﬂux pumps
recognize a spectrum of noxious agents, including antibiotics such as
tetracycline, and extrude these from the bacterial cytoplasm.6 Selective
serotonin reuptake inhibitor compounds may also produce an anti-
microbial response by themselves, a mechanism that is only poorly
understood and investigated. In E. coli, the tripartate AcrAB-TolC
system is the best-studied efﬂux pump system. Sertraline, a selective
serotonin reuptake inhibitor compound, has been shown to decrease
the MIC of tetracycline for strains that overproduce the AcrAB-TolC
pump system.7
In addition, antibiotic-speciﬁc efﬂux pumps; for example, the TetA
pump, which is a proton-motive force-dependent tetracycline-speciﬁc
pump,8 is frequently observed in highly antibiotic-resistant bacteria.
TetA pumps are commonly found in E. coli strain with clinically
relevant tetracycline resistance,9 but how sertraline impact tetA-
encoded resistance remains to be investigated.
The aim of the present study was to investigate the effect of
combined sertraline and tetracycline exposure to evaluate the ‘helper-
compound’ properties of sertraline against tetA-encoded tetracycline
resistance in E. coli. To elucidate the mechanism behind the synergy
observed between sertraline and tetracycline, the global transcriptomic
response of a tetA-encoded tetracycline-resistant E. coli was further
characterized.
MATERIALS AND METHODS
Bacterial strain characteristics and susceptibility testing
The MIC for sertraline hydrochloride and tetracycline (Sigma, Copenhagen,
Denmark) were determined for a collection of 84 E. coli isolates. The strains
originated from a random collection of porcine commensal E. coli strains from
the strain collection of Department of Veterinary and Animal Sciences, UCPH.
The MIC of some of the strains have previously been reported,10 but the MIC
determination was repeated in the current investigation.
The tetracycline-resistant strain, E. coli APEC_O2, was chosen for detailed
characterization of the response of tetracycline-resistant E. coli to sertraline,
tetracycline or a combination hereof. The isolate originates from a diseased
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chicken.11 It possesses a resistance plasmid encoding resistance towards eight
different anti-microbials, including tetracycline.12 In E. coli APEC_O2, tetra-
cycline resistance is mediated by a tetracycline-speciﬁc efﬂux pump, TetA.13
The MIC determination was carried out following CLSI guidelines.14
Mueller–Hinton (MH) broth (Sigma) was supplemented with tetracycline or
sertraline and distributed in individual microtiter plates with twofold dilution
increase, in concentrations of the compounds ranging from 0 to 1024 mg l− 1
and 0 to 128 mg l− 1 for tetracycline and sertraline, respectively. pH of the MH
broth was measured for MH broth unsupplied and supplied with the maximum
concentration of each compound. E. coli in saline suspensions were prepared
from overnight cultures on blood agar and adjusted to a 0.5 McFarland
turbidity standard. The suspensions were diluted 1:100 in MH and this
suspension was used as inoculum of the wells, giving a ﬁnal concentration of
~ 5×105 CFU ml− 1. After twice determination of MIC for tetracycline and
sertraline for each strain, MIC of tetracycline was subsequently determined
twice in broth supplemented with ½ MIC of sertraline, otherwise following the
description above. The inoculated microtiter plates were incubated aerobically
at 37 °C for 18–22 h.
For sertraline, the MBC was determined by plating 100 μl from wells where
no growth was observed onto MH agar plates. The plates were incubated at 37 °
C for 18–20 h before growth was determined. The MBC was classiﬁed as the
concentration where ⩾ 99% reduction in bacterial cell count was observed
compared with CFU of 100 μl untreated culture of the same strain.
MIC for tetracycline for E. coli APEC_O2 cocultured with known inhibitors
of general efﬂux pumps (Phe-Arg β-naphthylamide, chlorpromazine and
thioridazine (Sigma), respectively) was determined according to the method
stated above.
The MIC of penicillin, kanamycin and erythromycin (all compounds
obtained from Sigma), with and without supplementation with ½ MIC of
sertraline, were determined for strain APEC_O2 as well.
Growth conditions
Growth experiments were performed in triplicate on a BioScreen C (Oy
Growth Curves Ab, Helsink, Finland) for 24 h at 37 °C. A volume of 200 ml of
MH broth was inoculated with a culture of E. coli APEC_O2 growing overnight
to a ﬁnal cell density of 106 CFU ml− 1. The concentration of the culture was
adjusted using a Sensititer Nephelometer (Thermo Scientiﬁc TM, Roskilde,
Denmark) with a 0.5 McFarland standard (1–2× 108 CFU ml− 1). The cultures
were supplemented with sertraline and tetracycline alone or in combination. An
untreated control was included. The OD (recorded with a 600 nm ﬁlter) was
measured every 5 min with continuous shaking.
Time-kill assays (triplicates) were used to determine the rate of bacterial
killing when exposed to sertraline and/or tetracycline following a previously
described protocol.15 E. coli APEC_O2 was grown to early exponential phase
and treated with concentrations equivalent to either ½ MIC of sertraline, ½
MIC of tetracycline or ½ MIC of sertraline combined with ½ MIC of
tetracycline in MH broth. Growth was monitored by OD600 measurements
on a Helios spectrophotometer (Thermo Electron Corporation Instrument,
Beverly, MA, USA) and by CFU ml− 1 determinations by plating 10-fold serial
dilutions on MH agar plates.
Checkerboard assays
Synergistic effect of sertraline on tetracycline activity against E. coli APEC_O2
was evaluated by checkerboard method with 96-well microtiter plates using
MH broth, as described elsewhere.16 For each combination, the fractional
inhibitory concentration (FIC) was calculated as the MIC of the tetracycline in
combination sertraline divided by the MIC of the tetracycline alone and
likewise for sertraline. The FIC indexes were derived from summation of
individual FICs.17
Isolation of total cellular RNA
RNA was isolated from APEC_O2 exposed to three different treatments
(sertraline (16 mg l− 1), tetracycline (32 mg l− 1) or a combined treatment of
sertraline (8 mg l− 1) and tetracycline (4 mg l− 1) in addition to an untreated
control. The concentrations corresponded to ½ MIC for individual tetracycline
or sertraline treatment, and to ½ MIC for tetracycline/sertraline combined
treatment. For each growth condition, three colonies of APEC_O2 cultured at
37 °C in MH broth unsupplemented or supplemented with sertraline, tetra-
cycline or sertraline/tetracycline (ST) in the concentrations stated above,
allowing bacteria to reach the early logarithmic growth phase (OD600=
0.2–0.4). RNA from each of three replicates of each growth conditions were
extracted using the RiboPure Bacteria Kit (Thermo Fisher Scientiﬁc) according
to the manufacturer's instructions. RNA extraction samples were subjected to
DNAse treatment and cleanup using the RNeasy Kit (Qiagen, Hilden,
Germany). RNA integrity was conﬁrmed using a TapeStation with RNA
High-Sensitivity Screen Tapes (Agilent).
Library preparation and sequencing
rRNA was removed by the RiboPure Kit (Illumina, Little Chesterford, UK).
Transcriptome libraries were prepared using the stranded TruSeqmRNAseq
protocol, which enables strand-speciﬁc identiﬁcation of transcripts. The 12
samples were pooled in equimolar concentrations and sequenced on an
IlluminaMiSeq using the 1× 150 bp MiSeq Reagent Kit v.3 (Illumina).
Bioinformatic processing and analysis
Raw sequence reads in fastq format were trimmed using Trimmomatic v.0.36
with the settings; LEADING:3TRAILING:3 SLIDINGWINDOW:4:15 MIN-
LEN:50 and removing Illumina adapters if found.18 The trimmed transcrip-
tome reads were mapped to features annotated as CDS, rRNA or tRNA in the
annotated genome of E. coli APEC_O2 and the two associated plasmids
pAPEC-O2-CoIV and pAPEC-O2-R, using bowtie-2 as default parameters.19
For each mapping the number of reads mapping to a speciﬁc gene was
calculated using a simple command line script: grep ‘ˆ@’-v map.sam | cut -f3 |
sort | uniq -c4result.txt. The count tables were imported to R processed using
the default DESeq2 workﬂow,20 and visualized using ggplot2. Principal
component analysis (PCA) of overall sample similarity was carried out using
DESeq2 normalized counts (square root transformed), through the vegan21
ampvis R packages.22
KEGG pathway analysis was carried out by annotating each gene with a KO
identiﬁer using the bidirectional best hit method implemented in the
KEGG Automatic Annotation Server (http://www.genome.jp/tools/kaas/).23
The output KO identiﬁers were further analyzed using MinPath,24 and the
results were imported to R.
Analysis of gene expression
The DESeq2 workﬂow was applied to normalize the read counts and identify
differential expressed genes.20 Counts from rRNA genes were removed before
the analysis. Functional enrichment analysis with regard to gene ontology
categories was performed using the Cytoscape plugin BINGO.25 The signiﬁ-
cantly regulated pathways were selected based on the false discovery rate
(Benjamini–Hochberg multiple testing correction).26 KEGG database was used
to further analysis differentially expressed genes.27 Only genes which were
regulated with at least twofold compared with control conditions were included
for KEGG and functional enrichment analyses.
RESULTS
Phenotypic effect of sertraline on tetracycline-resistant E. coli
MIC for sertraline ranged from 16 to 32 mg l− 1 and from 32 to
1024 mg l− 1 for tetracycline for a collection of 84 tetracycline-
resistant E. coli isolates (Table 1). For all strains, the MIC of
tetracycline could be reduced with at least 50% in the presence of ½
Table 1 MIC values for sertraline and tetracycline for a collection of
84 tetracycline-resistant strains of E. coli
MIC50 MIC90 MIC (lowest–highest)
Sertraline 32 32 16–32
Tetracycline 128 512 32–1024
Tetracycline (+½ MIC sertraline) 16 64 1–512
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MIC of sertraline. For all isolates, MIC of sertraline was equivalent to
MBC of the same drug.
The MICs of penicillin, erythromycin and kanamycin of E. coli
APEC_O2 were not decreased when dilutions tubes were supplemen-
ted with ½ MIC concentrations of sertraline (Table 2), indicating that
the effect was speciﬁc to tetracycline among these drugs.
Exposure of E. coli APEC_O2 to increasing concentrations of
sertraline revealed that sertraline affects bacterial growth rate in a
concentration-dependent manner (Figure 1), and at a concentration
above ½ MIC (18 mg l− 1), there was an increased lag phase.
Synergy as deﬁned by Odd,17 corresponding to an FIC index ⩽ 0.5,
was obtained for E. coli APEC_O2 with 8 mg l− 1 sertraline and
16 mg l − 1 of tetracycline. The checkerboard assay also revealed that ½
MIC of sertraline (16 mg l− 1) was sufﬁcient to lower the MIC of
tetracycline from 64 to 4 mg l− 1.
Compound inhibition of broad-speciﬁcity efﬂux pumps only had
limited impact on tetracycline resistance of E. coli APEC_O2 (Table 2).
Time-kill curves revealed that the CFU for E. coli APEC_O2 exposed
to ½ MIC of a combination of sertraline and tetracycline was reduced
~ 4 log10, compared with treatment with ½ MIC of sertraline,
tetracycline or untreated control (Figure 2).
Transcriptome analysis of tetracycline-resistant E. coli treated with
sertraline
RNA sequencing was performed on E. coli APEC_O2 treated with
tetracycline and/or sertraline. After the quality control, 1.3 to 2.2
million reads generated per sample. Of the mapped reads, ~ 70%
mapped to annotated genes in APEC_O2. A violin plot revealed that
sequencing resulted in ~ 50–500 reads per gene per sample, which
enabled comprehensive investigation of the complete transcriptome.
The analysis identiﬁed the expression of 5168 coding DNA sequencing
tags. A PCA of the normalized gene expression data from DESeq2
showed that the samples tightly clustered based on treatment
condition and that selected genes were upregulated under speciﬁc
conditions (Figure 3). The PCA also revealed that the ST-exposed
samples clustered furthest from the unexposed control on the ﬁrst
dimension compared (maximal variations in differentially expressed
genes to sertraline- and tetracycline-treated samples). Overall, ST
induced a higher number of differentially expressed genes compared
with either sertraline or tetracycline treatment vs control condition
(Table 3 and Figure 4).
Overviews of the 50 differentially expressed genes with lowest
adjusted P-value (all Po0.001) between ST and control treatment, ST
treatment vs tetracycline treatment and ST treatment vs sertraline
treatment are presented in Tables 4–6, respectively. A total of 1705
signiﬁcantly regulated genes could be assigned to 18 functional groups
deﬁned by KEGG (Supplementary Figure S1). Of these, 1278 were
signiﬁcantly regulated under ST treatment, whereas the corresponding
numbers for sertraline and tetracycline treatment were 547 and 605,
respectively (Table 3).
Initially, KEGG Mapper was applied to visualize pathways including
genes, which were signiﬁcantly regulated under ST treatment. Among
the upregulated pathways were the ribosome subunits, which had 54
genes assigned, followed by the purine metabolism (21), the two-
component system (20), the pyrimidine metabolism (18), carbon
metabolism (13), ABC transporters (13) and glycolysis (11), while a
number of other pathways had between 10 and 0 genes assigned each.
Subsequently, functional enrichment analysis was applied using
Cytoscape with the plugin BINGO. Here, 300 gene ontology categories
were identiﬁed, of which 174 were signiﬁcantly regulated (Po0.05).
The most signiﬁcantly upregulated pathways corresponded to the
output from KEGG Mapper.
Expression of tetA, encoding the TetA pump, and tetR, encoding the
TetA repressor, differed between E. coli APEC_O2 exposed to different
treatments (Table 7). Under the ST and tetracycline treatments, tetR as
well as tetA were signiﬁcantly upregulated, the latter by more than 32-
fold in both treatments, whereas neither of the genes were regulated
signiﬁcantly under sertraline treatment alone compared with control
conditions. However, the ratio between the tetA:tetR under tetracycline
treatment (2.8) was compared with the tetA:tetR ratio under ST
treatment (2.4).
Genes encoding AcrAB (acrA and acrB) were the most signiﬁcantly
downregulated efﬂux pump genes across all treatment groups.
Table 2 MIC values for sertraline, tetracycline and tetracycline in
combination with sertraline or other agents known to be inhibitors of
efﬂux pumps in E. coli
E. coli APEC_O2
MIC (μg ml−1) MBC (μg ml−1)
Tetracycline Sertraline 64 128
32 32
Tetracycline +1/2 MIC sertraline 4 4
Tetracycline +20 μg ml−1 PAN 64 —
Tetracycline+1/2 MIC TDZ 32 —
Tetracycline+1/2 MIC CHL 64 —
Abbreviations: CHL, chlorpromazine; PAN, Phe-Arg β-naphthylamide; TDZ, thioridazine.
Figure 1 Growth curves of E. coli APEC_O2 exposed to increasing
concentrations of sertraline.
Figure 2 Time-kill curve of E. coli APEC_O2 exposed to tetracycline,
sertraline, a combination thereof, or untreated control conditions (Mueller–
Hinton (MH) broth).
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Sertraline treatment induced the most signiﬁcant downregulation,
followed by tetracycline treatment.
Among all pathways, the ribosomal pathways had the highest
number of signiﬁcantly regulated genes assigned; hence, the ribosomal
and purine metabolic pathways were the most signiﬁcantly upregu-
lated categories. All the ribosomal encoding genes were signiﬁcantly
upregulated under ST vs tetracycline treatment (Table 5) even though
the tetracycline concentration was eight times in tetracycline treatment
compared with ST treatment. The upregulation was not due to the
effect of sertraline, as no ribosomal encoding genes were upregulated
under sertraline treatment (Tables 5 and 6).
Figure 3 Overall sample comparison using principal component analysis (PCA). PCA was used to compare the global gene expression between all samples (C:
control; S: sertraline treatment; ST: sertraline and tetracycline treatment; T: tetracycline treatment). Samples located together have similar gene expression.
Genes (gray dots) located in the same direction as samples have higher expression in those sample.
Table 3 Summary of the total number of genes signiﬁcantly up/down
genes in E. colia
Conditions compared Total number of regulated genes Up Down
Control vs sertraline 535 317 218
Control vs tetracycline 593 344 249
Control vs sertraline+ tetracycline 1311 672 639
Sertraline vs sertraline+tetracycline 1002 530 472
Tetracycline vs sertraline
+tetracycline
1138 601 537
Sertraline vs tetracycline 640 324 316
Abbreviations: Up/down, up- or downregulated.
aAPEC_O2 exposed to sertraline, tetracycline or a combination hereof vs untreated control
conditions.
Figure 4 Venn diagram comparisons of control (C) vs treatments (sertraline
(Ser), tetracycline (Tet), tetracycline+sertraline (ST). Numbers in bold
indicate number of upregulated genes and non-bold indicate number of
downregulated genes.
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Table 4 The 50 most signiﬁcant differentially expressed genes in E. colia
Relative expressions of mRNA Description (functional group)
Treatment
Ser+Tet (8 mg l−1+4 mg l−1) Tet (32 mg l−1) Ser (16 mg l−1)
Downregulated
ridA Reactive intermediate/imine deaminase (V) −5.57 0.05 0.90
yghZ Aldo/keto reductase (− ) −3.41 0.14 −0.10
osmY Hypothetical protein (S) −4.77 0.53 0.11
malP Maltodextrin phosphorylase (G) −4.11 −1.08 −2.58
elaB Protein ElaB (J) −4.15 −1.58 −1.27
dhnA Fructose-bisphosphate aldolase (G) −5.13 −3.12 −0.73
lacZ Beta-D-galactosidase (G) −6.69 0.17 −0.55
celF Alpha-glucosidase/alpha-galactosidase (G) −5.53 0.13 −0.63
malQ 4-alpha-glucanotransferase (G) −4.77 −0.92 −2.29
NA Hypothetical protein (− ) −5.97 −5.38 −4.86
brf Bacterioferritin (P) −4.46 −2.11 −1.73
pduW Propionate kinase (C) −6.40 0.38 1.16
hchA Chaperone protein HchA (R) −4.44 −2.02 −1.80
ppsA Phosphoenolpyruvate synthase (G) −3.79 −0.41 0.57
NA Hypothetical protein (− ) −5.00 −0.98 −2.01
wrbA NAD(P)H:quinone oxidoreductase (C) −5.00 −0.90 −1.98
lamB Maltoporin (G) −6.92 −1.05 −6.91
ilvA Threonine dehydratase (E) −6.01 0.22 −0.92
tdcE PFL-like enzyme TdcE (C) −5.55 −0.08 1.22
sdaC HAAAP family serine/threonine permease (E) −5.93 0.45 1.55
gadA Glutamate decarboxylase (E) −5.43 −5.19 −3.48
malE Maltose ABC transporter substrate-binding protein (G) −6.64 −2.02 −5.40
gadC Glutamate:gamma-aminobutyrate antiporter −5.71 −4.82 −3.56
ﬂgL Flagellin (N) −6.93 −5.66 −6.98
NA Hypothetical protein (− ) −2.77 −0.88 −0.96
Upregulated
rpoA DNA-directed RNA polymerase subunit alpha (K) 2.13 0.77 0.06
rplO 50S ribosomal protein L15 (J) 2.24 0.84 0.27
rplJ 50S ribosomal protein L10 (J) 2.23 0.45 0.28
glnH Glutamine ABC transporter substrate-binding protein (E) 2.53 −0.82 −0.22
rppL 50S ribosomal protein L16 (J) 2.50 0.32 0.18
mdh Malate dehydrogenase (C) 2.15 0.56 1.75
citF Citrate lyase subunit alpha (C) 6.63 −1.25 5.58
typA GTP-binding protein TypA (T) 2.60 0.38 0.63
rplK 50S ribosomal protein L11 (J) 2.22 0.45 0.03
ptaN Phosphate acetyltransferase (R) 2.38 −1.35 1.18
glnQ Glutamine ABC transporter ATP-binding protein (E) 3.23 −0.45 0.19
priB Primosomal replication protein N (L) 2.69 0.82 0.47
rplQ 50S ribosomal protein L17 (J) 2.18 0.97 0.08
rplA 50S ribosomal protein L1 (J) 2.34 0.55 0.09
rpsF 30S ribosomal protein S6 (J) 2.77 0.71 0.32
ackA Acetate kinase (C) 2.45 −1.08 0.88
guaB IMP dehydrogenase (T) 4.23 1.27 1.37
glnA Glutamine synthetase (E) 4.25 −0.19 0.82
pykF Pyruvate kinase (G) 2.61 −0.73 −0.21
alkP 2,3-bisphosphoglycerate-independent phosphoglycerate mutase (G) 3.02 −0.67 0.09
ptsG PTS glucose-speciﬁc subunit IIBC (G) 3.57 −0.28 0.05
guaA GMP synthase (E) 3.49 0.18 0.80
citT Anion permease (G) 8.31 −0.76 6.49
asr Acid-shock protein (− ) 8.29 −1.31 8.97
Abbreviations: Ser, sertraline; Tet, tetracycline.
aAPEC_O2 treated with either Ser or Tet combined Tet and Ser (ST) vs control conditions. The change in expression is relative to control condition, and values are stated as log 2 fold-change. For
completeness, the gene regulatory levels of Ser- and Tet-only treatments vs control condition for the same 50 genes are also included in the table. Values in bold are signiﬁcantly different from
control.
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Table 5 The 50 most signiﬁcant differential expressed genes in E. colia
Relative expressions of mRNA Description (functional group)b
Treatment
Ser+Tet (8 μg ml−1+4 μg ml−1) Tet (32 μg ml−1) Ser (16 μg ml−1)
Upregulated
pkg Phosphoglycerate kinase (G) 1.79 −0.53 −0.33
pgi Glucose-6-phosphate isomerase (G) 0.73 −1.16 −0.25
aphC Alkyl hydroperoxide reductase (V) 1.36 −0.97 0.08
focA Formate transporter (P) 0.75 −1.96 0.25
mnhD Formate hydrogenlyase subunit (C) 1.59 −3.09 −0.69
potE Arginine:agmatine antiporter (E) 1.53 −3.42 −3.37
tuf Elongation factor Tu (− ) 1.55 0.12 0.55
sdhA Fumarate reductase (C) 0.75 −1.29 0.73
hycE Hydrogenase 3 large subunit (C) 1.59 −2.53 −0.30
NA Transcriptional regulator (− ) 1.77 −3.01 −1.01
ptsH PTS sugar transporter (G) 2.22 −0.71 0.81
glnQ Glutamine ABC transporter ATP-binding protein (E) 3.32 −3.38 0.20
nrdD Anaerobic ribonucleoside triphosphate reductase (F) 2.24 −0.80 1.07
sseA Thiosulfate sulfurtransferase (P) 1.65 −2.14 0.41
tpiA Triose-phosphate isomerase (G) 1.00 −1.56 0.38
glnA Glutamine synthetase (E) 4.25 −0.19 0.80
glnH Glutamine ABC transporter substrate-binding protein (E) 2.53 −0.83 −0.22
ptsA Phosphoenolpyruvate-protein phosphotransferase (G) 1.54 −3.22 0.17
guaA GMP synthase (E) 3.50 0.18 0.81
idcC Arginine decarboxylase (E) 1.72 −3.05 −3.20
asr Acid-shock protein (− ) 8.29 −1.31 8.97
potA Spermidine/putrescine ABC transporter substrate-binding protein (− ) 1.67 −2.01 0.02
fdhF Formate dehydrogenase subunit alpha 1.56 −1.09 0.28
ptsG PTS glucose-speciﬁc subunit IIBC (G) 3.57 −2.28 0.01
citT Anion permease (G) 8.31 −2.27 6.49
eno Enolase (G) 1.25 −1.59 0.12
alkP 2,3-bisphosphoglycerate-independent phosphoglycerate mutase (G) 3.01 −0.67 0.08
ptaN Phosphate acetyltransferase (R) 2.38 −1.35 1.18
pykF Pyruvate kinase (G) 2.61 −0.73 −0.20
ackA Acetate kinase (C) 2.45 −1.08 0.88
gapA Glyceraldehyde-3-phosphate (G) 1.22 −1.85 0.19
fab Class II fructose-bisphosphate aldolase (G) 0.91 −1.83 −0.20
pﬂD Pyruvate formate-lyase (C) 1.24 −2.82 0.05
Downregulated
yghZ Oxidoreductase (− ) −3.41 0.14 0.10
ridA Reactive intermediate/imine deaminase (V) −5.57 0.05 0.90
traT Conjugal transfer surface exclusion protein TraT (− ) −0.80 1.55 0.63
NA Hypothetical protein (− ) −5.00 −0.99 −2.08
wrbA NAD(P)H:quinone oxidoreductase (C) −5.00 −0.90 −1.98
glgS Glycogen synthesis protein (− ) −2.25 2.16 −0.29
traS Conjugal transfer protein TraS −0.12 1.82 0.28
malE Maltose ABC transporter substrate-binding protein MalE (G) −6.64 −2.02 −5.40
lamB Maltoporin (G) −6.72 −1.05 −6.19
lacZ Beta-D-galactosidase (G) −6.89 0.17 −0.65
celF Alpha-glucosidase/alpha-galactosidase (G) −5.53 0.13 0.63
ppsA Phosphoenolpyruvate synthase (G) −3.79 −0.41 0.57
tdcD Propionate kinase (C) −6.40 0.38 1.16
tdcE PFL-like enzyme TdcE (C) −5.54 0.08 1.23
ilvA Threonine dehydratase (E) −6.08 0.86 0.01
sdaC HAAAP family serine/threonine permease −5.93 −0.45 1.15
Abbreviations: Ser, sertraline; Tet, tetracycline.
aAPEC_O2 treated with Ser or Tet or combined Ser and Tet vs single treatment with Tet. The change in expression is relative to control condition, and values are stated as log 2 fold-change. For
completeness, the gene regulatory level of Ser vs control condition for the same 50 genes is also included in the table. Values in bold are signiﬁcantly different from control.
bAccording to KEGG classiﬁcation: C, energy production and conversion; E, amino-acid transport and metabolism; V, defense mechanism; G, carbohydrate transport and metabolism; P, inorganic
transport and metabolism; T, signal-transduction mechanisms; J, translation, ribosomal structure and biogenesis; R, general function prediction only; NA, not available.
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Table 6 The 50 most signiﬁcant differential expressed genes in E. colia
Relative expression of mRNA Description (functional group)b
Treatment
Ser+ Tet (8 μg ml−1+4 μg ml−1) Tet (32 μg ml−1) Ser (16 μg ml−1)
Upregulated
pykF Pyruvate kinase (G) 2.62 −0.73 −0.20
ptsG1 PTS glucose-speciﬁc subunit IIBC (G) 3.57 −0.28 0.01
ldcC Arginine decarboxylase 1.72 −3.05 −3.20
alkP Phosphoglycerate mutase (G) 3.02 −0.67 0.08
NA Hypothetical protein (S) −0.19 −0.92 −4.25
rplA 50S ribosomal protein L1 (J) 2.34 0.55 0.09
glnH Glutamine ABC transporter substrate-protein (C) 2.54 −0.83 −0.23
guaA GMP synthase (E) 3.50 0.18 0.81
rplQ 50S ribosomal protein L17 (J) 2.18 0.97 0.08
rplK 50S ribosomal protein L11 (J) 2.22 0.45 −0.03
rpsF 30S ribosomal protein S6 (J) 2.77 0.71 0.32
glnA Glutamine synthetase (E) 4.25 −0.19 0.82
glnQ Glutamine ATP-binding protein (E) 3.23 −0.45 0.19
rpoA DNA-directed RNA polymerase subunit alpha (K) 2.13 0.78 0.05
rpsQ 30S ribosomal protein S17 (J) 2.16 0.43 0.02
rpsD 30S ribosomal protein S4 (J) 1.97 0.64 0.00
rppL 50S ribosomal protein L16 (J) 2.50 0.32 0.18
potE Arginine:agmatine antiporter (E) 1.53 −3.25 −3.74
hisJ Amino-acid transporter (E) 2.04 −0.44 −0.80
NA 50S ribosomal protein L29 (J) 2.56 0.47 0.18
araC Transcriptional regulator (K) 2.25 −1.20 −2.15
rpsM 30S ribosomal protein S13 (J) 1.95 0.54 −0.03
pgk Phosphoglycerate kinase (G) 1.80 −0.54 −0.32
rplJ 50S ribosomal protein L10 (J) 2.33 0.45 0.28
rpsK 30S ribosomal protein S11 (J) 2.05 0.74 0.04
priB Primosomal replication protein N (L) 2.69 0.82 0.47
Downregulated
sdaC HAAAP family serine/threonine permease (E) −5.94 0.45 1.15
tdcE PFL-like enzyme TdcE (C) −5.54 0.08 1.22
ilvA Threonine dehydratase (E) −6.08 0.21 0.91
rbsB ABC transporter substrate-binding protein (G) −2.64 0.28 3.10
ackA Propionate kinase (C) −6.41 0.38 1.16
ppsA Phosphoenolpyruvate synthase (G) −3.79 −0.41 0.57
galT Galactokinase (G) −2.19 0.92 1.75
galM Galactose mutarotase (G) −1.94 0.72 1.77
ridA Reactive intermediate/imine deaminase (− ) −5.58 −0.05 0.90
csrA Carbon starvation protein A (− ) −2.57 −0.72 2.09
glpQ Glycerophosphoryl diester phosphodiesterase (I) −0.53 0.87 3.26
lacZ Beta-D-galactosidase (G) −6.70 0.17 −0.55
nuoG Oxidoreductase (− ) −3.41 −0.14 −0.10
celF Alpha-glucosidase/alpha-galactosidase (G) −5.53 0.13 −0.62
ansB L-asparaginase (J) −2.07 0.98 1.28
rbsK Ribokinase (G) −0.66 0.14 2.55
sdaA Serine dehydratase (E) −5.45 −0.04 1.24
dhnA Fructose-bisphosphate aldolase (G) −5.13 −3.12 −0.72
galE Galactose-1-phosphate uridylyltransferase (G) −1.64 0.66 1.43
proP D-galactose transporter GalP (− ) −2.18 −0.54 0.43
rbsC Ribose ABC transporter permease (G) −1.33 0.47 3.45
glpT Glycerol-3-phosphate transporter (G) 2.16 2.37 4.98
NA Hypothetical protein (− ) 0.09 0.24 2.42
Abbreviations: Ser, sertraline; Tet, tetracycline.
aAPEC_O2 treated with Ser or Tet or combined Ser and Tet vs individual sertraline treatment. The change in expression is relative to control condition, and values are stated as log 2 fold-change.
For completeness, the gene regulatory levels of individually tetracycline treatments vs control condition for the same 50 genes are also included in the table. Values in bold are signiﬁcantly different
from control.
bAccording to KEGG classiﬁcation: C, energy production and conversion; E, amino-acid transport and metabolism; V, defense mechanism; G, carbohydrate transport and metabolism; P, inorganic
transport and metabolism; T, signal-transduction mechanisms; J, translation, ribosomal structure and biogenesis; R, general function prediction only; NA, not available.
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Genes encoding for glycolytic process were also among the most
signiﬁcantly upregulated in ST treatment vs tetracycline and sertraline
treatment, and control conditions (Tables 4–6). The citT and asr
genes, encoding a citrate/succinate antiporter and acid-shock protein,
respectively, were more than 250-fold upregulated in ST treatment
(Tables 5 and 6).
Treatment of E. coli APEC_O2 with ST led to 438 uniquely
downregulated genes (Figure 4). KEGG Mapper revealed that these
genes were involved in carbon metabolism (27), amino acids
biosynthesis (21), ABC transporters (17), glyoxylate metabolism
(14), starch and sucrose metabolism (11), tricarboxylic acid cycle
(10), while a number of other downregulated pathways had between 9
and 0 genes assigned
In the functional enrichment analysis, the signiﬁcantly down-
regulated genes were assigned to 120 gene ontology categories, in
which 59 categories were signiﬁcantly regulated. The functional
analysis conﬁrmed the ﬁndings by KEGG, and also revealed an overall
decreased oxidative–reduction process pathway (Po0.0001). Similarly,
energy derivation by oxidation of organic compounds was also highly
signiﬁcantly downregulated under ST treatment only (Po0.001).
In addition to the above, cellular respiration as well as the
respiratory electron transport chain and generation of precursor
metabolites pathways were among the most signiﬁcantly downregu-
lated categories.
DISCUSSION
In the current study, we document that sertraline in subinhibitory
concentrations reduced MIC of tetracycline for 84 tetracycline-
resistant strains of E. coli, and restored the sensitivity of tetracycline
in E. coli APEC_O2 as deﬁned by EUCAST.28 Growth curves of E. coli
APEC_O2 exposed with various concentration of sertraline and/or
tetracycline indicated a concentration-dependent decrease of growth
rates (Figure 1), whereas the checkerboard analysis documented that
the two compounds do indeed have a synergistic interaction.
Combination of sertraline with other classes of antibiotics did not
decrease the MIC for these antibiotics (Table 2), which also support
that sertraline interacts synergistically with tetracycline, rather than
considering growth inhibition as a simple ‘two-hit model’.
The synergistic interaction between sertraline and tetracycline did
not occur as a result of sertraline acting as a broad-spectrum efﬂux
inhibitor. General efﬂux inhibitors did not restore tetracycline
sensitivity of E. coli APEC_O2, although sertraline treatment did
result in reduced expression of acrA and acrB (Tables 2 and 7). In
terms of antibiotic combination treatments, it is well known that
bacteriostatic–bactericidal combination treatments results in attenua-
tion of bactericidal activity in vitro.29–31 Single treatment with sertra-
line revealed that for this compound, MBC equaled MIC (Tables 1
and 2), a phenotypic observation indicative of a bactericidal
compound.32 Newer research suggests that bactericidal and bacterio-
static antibiotics differentially perturb bacterial cellular respiration, in
which the former accelerates respiration, whereas the latter decelerates
cellular respiration.33 In accordance with that research, we found that
tetracycline downregulated genes involved in cellular respiration,
whereas sertraline treatment did not affect cellular-respiration genes.
This differential activity, according to Lobritz et al.,33 would imply that
sertraline is not a ‘true’ bactericidal antibiotic. However, the combined
treatment of E. coli with sertraline and tetracycline signiﬁcantly
downregulated the cellular-respiration and tricarboxylic acid cycle.
Respiration is necessary for the reoxidation of NADH, which is
coupled to the generation of a proton gradient that is used, among
many processes, to drive ATP production via proton inﬂux through
the F1F0 ATPase stator.
34 Lack of cellular respiration will therefore be
followed by a lower proton gradient, which might be further decreased
by protonation of the amino group of sertraline in the bacterial
cytoplasm. Acid-shock genes were more than 300 times upregulated in
both ST treatment and sertraline treatment (Table 4), but down-
regulated under tetracycline treatment, supporting the hypothesis that
sertraline signiﬁcantly decreases pH. Also, sdaC encoding an H+/serine
symporter35 were more than 20-fold downregulated in ST treatment,
indicating that the bacteria is highly avoiding further acidiﬁcation. It is
noteworthy that, even at the MIC for sertraline (32 mg l− 1), a decrease
in pH of the growth medium by more than 0.2 was not observed,
leading to the conclusion that the acid-shock response is due to
intracellular decrease in pH only. Decrease in the proton gradient will
interfere with the TetA pump, which transports tetracycline from the
bacterial cytoplasm to the periplasm; the ﬂow of protons from the
periplasm to the cytoplasm provides the energy to the pump. The ﬂow
is dependent on a proton gradient between the periplasm and the
cytoplasm (Figure 5).8
Regulation of tetA, the TetA pump encoding gene, and tetR, a TetA
repressor gene, is highly dependent on the intracellular tetracycline
concentration, and the ratio of expression of tetA/tetR increases with
increasing concentration of tetracycline.13 Nevertheless, the results
obtained in the present study revealed a similar tetA/tetR ratio when
32 mg l− 1 tetracycline was administered (under tetracycline treatment)
and when only 4 mg l− 1 was administered (under ST treatment)
(Table 7). If the proton gradient between the cyto- and periplasm
decreases, a lower efﬁciency of the TetA pump will follow, and thereby
a higher cytoplasmic concentration of tetracycline will be present. If
Table 7 Regulation of tetR, tetA and genes related to porin and efﬂux
pump regulator/transport of E. colia
Relative expression of genes
Treatment
Sertraline Tetracycline Sertraline+tetracycline
tetA −0.70 6.17b 5.64b,c
tetR −0.02 2.23b 2.35b,d
ompC 1.03b 2.32b 0.48b,c
ompX 0.40b −0.11 1.95b,c
ompA 0.17 0.40b 0.96b,c
ompR 0.04 −0.35 0.64b,c
acrA −3.07b −2.18b −0.92b,c
acrB −2.80b −2.56b −1.01b,c
arcR 0.21 0.11 −0.61b,c
tolC −0.13 −0.75b 0.12e
marR 0.87 1.15b 2.66b,c
emrA 1.28b 1.46b 2.43b,c
emrB 0.58 0.61 1.64b,c
emrD −0.64 0.68b 0.37d
silA −0.45 −0.25 −1.35b,c
silE −0.71b 0.64b 0.35
silS −0.37 −0.44 −1.51b,c
silR −0.56 −0.56 −0.98b
silC −0.48 0.01 −0.88b
blaTEM-1 0.12 0.33 −0.35b,c
aAPEC_O2 under treatment with sertraline (16 mg l−1), tetracycline (32 mg ml−1) or sertraline/
tetracycline (8 and 4 mg l−1, respectively), compared with untreated control. Only genes of
which at least one treatment was signiﬁcantly different from untreated is stated in the table.
Change in regulation is stated as log 2 to value.
bSigniﬁcantly different from control.
cSigniﬁcant difference between sertraline/tetracycline vs control, sertraline and tetracycline,
respectively.
dSertraline/tetracycline different from sertraline treatment.
eSertraline/tetracycline signiﬁcantly different from tetracycline treatment.
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so, the cytoplasmic concentration of tetracycline will be higher if
sertraline is coadministered, and hence, the tetA/tetR ration would
diverge from what would be expected if tetracycline in the same
concentrations as used in the present study were administered without
sertraline.
Decrease of the electron transport chain, as indicated by down-
regulation of genes (nrfA, nrfD, nrfZ, cydA, cydB), will require other
processes to act as electron acceptors; for example, through fermenta-
tion, for the bacteria to grow. In fermentation, however, the pyruvate
made in glycolysis does not continue through oxidation and the
tricarboxylic acid. Essential genes in the glycolytic pathway (pgi, pkg,
pts, eno, pykA) to generate pyruvate were all upregulated under ST
treatment, as were pyruvate kinase (pykF), lactate dehydrogenase
(ldhA) and alcoholdehydrogenase (adhE), indicating that a direct
fermentation of pyruvate is occurring, generating lactate, as well as in
direct conversion of pyruvate to ethanol by using acetyl-CoA as an
intermediate treatment. The conversion of acetyl-CoA to ethanol is
particularly important to E. coli as this reaction generates two
molecules of the highly needed NAD+. Also in support of increased
fermentation, ST treatment led to the upregulation of mdh, fum and
frd genes, which encodes catalyzing proteins needed in the three-step
conversion of phosphoenolpyruvate to succinate under fermentation,
a process that also generates two molecules of NAD+. Genes encoding
conversion of acetyl-coA to acetate (pta, ackA) were also more highly
expressed under ST treatment compared with any of the other
conditions. Generation of lactate and acetate will further decrease
intracellular pH, which could explain why acid-shock proteins were
equally upregulated during ST and sertraline treatments, although two
times higher concentrations of sertraline was used in the latter
treatment.
Genes encoding for citrate lyase (citF) and a citrate/succinate
antitransporter, citT, were both upregulated more than 50-fold. citF
catalyses the cleavage of citrate under anaerobic conditions, whereas
citT is a citrate/succinate antiporter, responsible for the uptake of
citrate. Under anaerobic conditions, citrate can be used if an
oxidizable cosubstrate is present, such as glycerol or glucose.36 As
succinate is also the end product of citrate fermentation, citT
continues to feed the cell with citrate in the exchange for succinate,
which is pumped out of the cell.37 Finally, hyc encoding formate
hydrogenase lysase was upregulated in ST treatment only. Formate
hydrogenlyase uses protons to reduce formate during mixed-acid
fermentation,38 protecting the cell from the fermentation-related
acidic conditions. These ﬁndings all support the hypothesis that
fermentation is occurring under ST treatment only.
In conclusion, in vitro syngery between sertraline and tetracycline
was observed, independently of AcrAB efﬂux pump inhibition. An
intracellular acidiﬁcation, a shift from oxidation to fermentation and
decrease in PMF is suggested to be the main cause of synergy between
sertraline and tetracycline in E. coli APEC_O2.
Figure 5 Schematic model of synergy between sertraline and tetracycline in a TetA containing E. coli. The model is based on RNA sequencing data and
phenotypic obervations on MIC and MBC of tetracycline and sertraline, when E. coli APEC_O2 is exposed to each compound individually and combined. In
the non-protonated form, sertraline (Ser) can pass the outer membrane (OM) and inner membrane (IM) due to the lypophilic nature of the compound. In the
cytoplasm, sertraline is protonated, which causes a decrease in intracellular pH. According to the model of Berens and Hillen,8 tetracycline (Tet) in complex
with magnesium (not shown in ﬁgure) enters the OM through porins. In the periplasm, tetracycline can dissociate from the tetracycline–magnesium complex
and enter the cytoplasm by diffusion over the IM. After entering the cytoplasm, tetracycline can reach its ribomal (RS) target, unless it is actively extruted
from the cell by the TetA pump, which is indicated by the 12-α-helix structur. The TetA pump is driven by a proton-motive force energy. If sertraline
decreases the proton gradient, protons are not transfering through the inner membrane (indicated by a dashed line). If the TetA pump is not functional, the
tetracycline concentration will increase in the cell, which leads to increasing the expression of tetA and decreasing concentrations of tetR.13 When the
tetracycline concentration equals MIC for the strain, the translation from the ribosomes will be completely blocked and the cell will not be dividing. If
tetracycline is removed, the cell will start dividing again, hence MBC is higher than MIC. In concentrations of tetracycline below MIC, the cell will continue
to divide in the presence of tetracycline, yet there will be a partial shift from oxidation to fermentation. Fermenation will result in production of mixed fatty
acid, which will add to a futher decrease of intracelluar pH, ﬁnally resulting in a cellular collapse and cell death. Hence, when sertraline and tetracycline are
combined, the MIC of the combined exposure equals MBC. If E. coli is exposed only to sertraline, the cell will die when the concentrations of sertraline is
high enough to cause a lethal drop in intracelluar pH. This mode of action is largely independent of strain chracteristics, and equals ~32 μg ml−1 for E. coli
in general.
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